Document is current
Any future updates will be listed below
-
Authors
Mishra, Neha
Aden, Konrad
Blase, Johanna I.
Baran, Nathan
Bordoni, Dora
Tran, Florian
Conrad, Claudio
Avalos, Diana
Jaeckel, Charlot
Scherer, Michael
Sørensen, Signe B.
Overgaard, Silja H.
Schulte, Berenice
Nikolaus, Susanna
Rey, Guillaume
Gasparoni, Gilles
Lyons, Paul A.
Schultze, Joachim L.
Walter, Jörn
Andersen, Vibeke
,
Banos, Aggelos
Bertsias, George
Beyer, Marc
Boumpas, Dimitrios
Finckh, Axel
Franke, Andre
Georges, Michel
Gu, Wei
Häsler, Robert
Jawhara, Mohamad
Kenyon, Amy
Kratsch, Christina
Krause, Roland
Lauc, Gordan
Mangino, Massimo
Natoli, Gioacchino
Ostaszewski, Marek
Pezer, Marija
Raes, Jeroen
Rahmouni, Souad
Ramos-Pamplona, Marilou
Reiz, Benedikt
Rosati, Elisa
Sanoudou, Despina
Satagopam, Venkata
Schneider, Reinhard
Schulte-Schrepping, Jonas
Sidiropoulos, Prodromos
Smith, Kenneth G. C.
Spector, Timothy
Vandeputte, Doris
Vieira-Silva, Sara
Vojta, Aleksandar
Warnat-Herresthal, Stefanie
Zoldoš, Vlatka
Dermitzakis, Emmanouil T.
Schreiber, Stefan
Rosenstiel, Philip https://orcid.org/0000-0002-9692-8828
-
Funding
Funding for this research was provided by:
Horizon 2020 (733100)
Innovative Medicines Initiative (853995)
Deutsche Forschungsgemeinschaft (ExC 2167)
Universitätsklinikum Schleswig-Holstein - Campus Kiel
- License Information
-
More Information
Article History
Received: 11 January 2022
Accepted: 2 September 2022
First Online: 24 September 2022
Declarations
:
: The complete study was performed in accordance with the Declaration of Helsinki and approved by the ethics committee of the Christian-Albrechts-Universität zu Kiel (A 124/14 and AZ 156/03-2/13). All participating subjects of the study provided written informed consent.
: Not applicable
: Stefan Schreiber has been a consultant for AbbVie, Bristol Myers Squibb, Boehringer Ingelheim, Ferring, Genentech/Roche, Janssen, Lilly, Medimmune/AstraZeneca, Novartis, Merck Sharp Dohme, Pfizer, Protagonist, Sanofi, Takeda, Theravance, and UCB and is a paid speaker for AbbVie, Ferring, Janssen, Merck Sharp Dohme, Novartis, Takeda, and UCB. Philip Rosenstiel has been a consultant for Takeda and Omass. All other authors declare no competing interests.
